BPC-157
Body Protection Compound-157, The 'Healing Peptide'
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved; no marketed product anywhere in the world
Reference only. Not medical advice.
What can go wrong
Because there are no adequate human trials, the long-term safety profile is genuinely unknown. The FDA cited potential immunogenicity and peptide-related manufacturing impurities as concerns. Gray-market vials sold as 'research chemicals' are not made under GMP and may vary widely in purity, sterility, and actual peptide content. Its pro-angiogenic mechanism raises a theoretical concern about effects on occult tumors that has not been studied in humans.
This is something to take to a clinician. The Atlas can tell you what is known about bpc-157 in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
BPC-157 is a synthetic 15-amino-acid sequence said to be derived from a fragment of a protein found in human gastric juice. It is marketed for tendon, ligament, muscle, and gut healing and is one of the most-hyped 'recovery' peptides in the men's-optimization market. It has no FDA approval, no marketed product in any country, and essentially no controlled human trial data. The evidence base is almost entirely preclinical rodent work, much of it from a single Croatian research group.
The internet's favorite recovery peptide, with a near-empty human evidence file.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Preclinical work proposes BPC-157 promotes angiogenesis (partly via VEGFR2 and nitric-oxide pathways), modulates growth-factor expression, and accelerates fibroblast and tendon-cell activity. These mechanisms are described almost entirely in rats; whether any of it translates to systemically dosed humans is unestablished.
The evidence problem the ads skip
A 2025 systematic review of BPC-157 in orthopaedic applications screened 544 articles and found only a single human clinical study met inclusion criteria. The rodent literature is heavily concentrated in one research group, raising independent-replication concerns. Marketing that presents BPC-157 as a proven human healing agent is running far ahead of the data.
What people get wrong
Often said'BPC-157 is a proven healing peptide.'
ActuallyIt is proven in rodents by a narrow literature and essentially untested in controlled human trials. 'Proven' is not an accurate description of the human evidence.
Often said'It's natural, it comes from your stomach.'
ActuallyThe marketed compound is a synthetic stable fragment loosely attributed to a gastric-juice protein; the 'natural' framing overstates the connection and says nothing about safety of injecting it.
Who profits, and who pushes back
FDA (2023 bulks guidance)
Flagged BPC-157 for immunogenicity risk, impurity concerns, and insufficient safety data for human use.
How we got here
BPC-157 emerged from Croatian gastroenterology research in the 1990s exploring cytoprotective fragments in gastric juice. It stayed an obscure preclinical curiosity for two decades before the biohacking, TRT-clinic, and social-media 'recovery peptide' boom of the late 2010s and 2020s propelled it into mainstream men's-health marketing.
- 1990sBPC-157 described in Croatian gastroprotection research
- 2010sAdopted by biohackers and bodybuilding forums as a 'recovery peptide'
- Sept 2023FDA places BPC-157 in Category 2 of the interim 503A bulk-substances list (safety concerns)
- April 2026FDA removes BPC-157 (with 11 other peptides) from Category 2 and schedules it for Pharmacy Compounding Advisory Committee (PCAC) review
- July 23-24, 2026PCAC sessions scheduled to evaluate BPC-157 and related peptides
What we do not know
- Does any oral or injected BPC-157 benefit replicate in controlled human trials?
- Is systemic dosing safe long-term, given the pro-angiogenic mechanism?
- Will the July 2026 PCAC review move it toward a defined compounding pathway or away from one?
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Consumers obtain it through research-chemical websites, some telehealth/anti-aging clinics, and international vendors. Legitimacy, dose accuracy, and sterility vary enormously between sources.
Overwhelmingly sold online as a 'research chemical, not for human consumption,' or via compounding pharmacies before/around the 503A restrictions. Third-party testing of gray-market research peptides has reported purity well below pharmaceutical standard and possible endotoxin contamination.
At a glance
- Amino acids
- 15 (pentadecapeptide)
- Origin sequence
- Fragment attributed to gastric juice protein
- Human RCTs
- Effectively zero
- Marketed product
- None anywhere
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about BPC-157. A short entry is not a safe entry.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Sikiric et al. (Croatian group) rodent tendon/ligament series2000s-2010s
Repeated reports of accelerated healing in rats; foundational to nearly all BPC-157 marketing
Systematic review, orthopaedic BPC-1572025
Of 544 articles screened, only 1 human clinical study met inclusion criteria